IFRX
IFRX
NASDAQ · Biotechnology

Inflarx Nv

$2.47
+0.09 (+3.78%)
As of May 16, 2:18 AM ET ·
Financial Highlights (FY 2026)
Revenue
27.0K
Net Income
-45,753,804
Gross Margin
-24,678.8%
Profit Margin
-155,587.4%
Rev Growth
D/E Ratio
0.02
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin -24,678.8% 28.8% 28.8% 28.8%
Operating Margin -164,539.4% -7.0% -6.8% -7.5%
Profit Margin -155,587.4% -7.4% -5.8% -6.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 27.0K 9.23M 9.01M 7.68M
Gross Profit -6,659,571 2.66M 2.60M 2.21M
Operating Income -44,400,970 -646,720 -609,627 -579,731
Net Income -45,753,804 -678,125 -522,642 -466,092
Gross Margin -24,678.8% 28.8% 28.8% 28.8%
Operating Margin -164,539.4% -7.0% -6.8% -7.5%
Profit Margin -155,587.4% -7.4% -5.8% -6.1%
Rev Growth +6.0% +24.9% +0.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 1.83M 6.26M 5.90M 6.22M
Total Equity 81.48M 27.81M 26.71M 29.49M
D/E Ratio 0.02 0.23 0.22 0.21
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -42,279,430 -963,511 -904,753 -762,039
Free Cash Flow -508,030 -465,093 -442,494